Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Ratio (2016 - 2025)

Neurocrine Biosciences' Equity Ratio history spans 16 years, with the latest figure at 0.7 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 0.86% year-over-year to 0.7; the TTM value through Dec 2025 reached 0.7, up 0.86%, while the annual FY2025 figure was 0.7, 0.86% up from the prior year.
  • Equity Ratio reached 0.7 in Q4 2025 per NBIX's latest filing, roughly flat from 0.7 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.77 in Q3 2024 to a low of 0.65 in Q1 2022.
  • Average Equity Ratio over 5 years is 0.7, with a median of 0.7 recorded in 2024.
  • Peak YoY movement for Equity Ratio: grew 26.98% in 2021, then dropped 8.77% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.66 in 2021, then grew by 8.75% to 0.72 in 2022, then fell by 4.79% to 0.69 in 2023, then rose by 1.45% to 0.7 in 2024, then increased by 0.86% to 0.7 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Equity Ratio are 0.7 (Q4 2025), 0.7 (Q3 2025), and 0.69 (Q2 2025).